UPDATE: Forma takes aim at Agios with new AML complete remission data
Forma Therapeutics went public this year and raised $320 million in large part on the strength of their Phase I/II sickle cell program. But …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
